CN114680233A - Application of cinnamaldehyde in preparing feed, feed additive, veterinary drug or water-drinking preparation for preventing or treating poultry adenoid myogastritis - Google Patents
Application of cinnamaldehyde in preparing feed, feed additive, veterinary drug or water-drinking preparation for preventing or treating poultry adenoid myogastritis Download PDFInfo
- Publication number
- CN114680233A CN114680233A CN202011591319.8A CN202011591319A CN114680233A CN 114680233 A CN114680233 A CN 114680233A CN 202011591319 A CN202011591319 A CN 202011591319A CN 114680233 A CN114680233 A CN 114680233A
- Authority
- CN
- China
- Prior art keywords
- feed
- cinnamaldehyde
- days
- preparation
- drinking water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 title claims abstract description 97
- 229940117916 cinnamic aldehyde Drugs 0.000 title claims abstract description 94
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 title claims abstract description 94
- 239000003674 animal food additive Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 48
- 244000144977 poultry Species 0.000 title claims abstract description 40
- 239000000273 veterinary drug Substances 0.000 title claims abstract description 29
- 241000321096 Adenoides Species 0.000 title claims description 16
- 210000002534 adenoid Anatomy 0.000 title claims description 16
- 208000007882 Gastritis Diseases 0.000 claims abstract description 31
- 206010017865 Gastritis erosive Diseases 0.000 claims abstract description 14
- 239000003651 drinking water Substances 0.000 claims description 35
- 235000020188 drinking water Nutrition 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 22
- 230000003628 erosive effect Effects 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 10
- 230000017448 oviposition Effects 0.000 claims description 9
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 6
- 241000411851 herbal medicine Species 0.000 claims description 6
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 6
- 239000000341 volatile oil Substances 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 5
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 3
- 239000005770 Eugenol Substances 0.000 claims description 3
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 3
- 239000005844 Thymol Substances 0.000 claims description 3
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 claims description 3
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 claims description 3
- 235000007746 carvacrol Nutrition 0.000 claims description 3
- 229960002217 eugenol Drugs 0.000 claims description 3
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229960000790 thymol Drugs 0.000 claims description 3
- 230000000762 glandular Effects 0.000 abstract description 34
- 239000003242 anti bacterial agent Substances 0.000 abstract description 11
- 229940088710 antibiotic agent Drugs 0.000 abstract description 11
- 230000035622 drinking Effects 0.000 abstract description 3
- 241000287828 Gallus gallus Species 0.000 description 126
- 235000013330 chicken meat Nutrition 0.000 description 99
- 235000013594 poultry meat Nutrition 0.000 description 31
- 238000011282 treatment Methods 0.000 description 25
- 210000002784 stomach Anatomy 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 21
- 238000012360 testing method Methods 0.000 description 17
- 235000021050 feed intake Nutrition 0.000 description 15
- 208000005641 Adenomyosis Diseases 0.000 description 14
- 238000009395 breeding Methods 0.000 description 14
- 230000001488 breeding effect Effects 0.000 description 14
- 201000009274 endometriosis of uterus Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 230000003387 muscular Effects 0.000 description 13
- 235000013601 eggs Nutrition 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 244000144992 flock Species 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 201000002481 Myositis Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 5
- 210000003746 feather Anatomy 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 229960003022 amoxicillin Drugs 0.000 description 4
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 4
- 235000014590 basal diet Nutrition 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 239000002115 aflatoxin B1 Substances 0.000 description 3
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 3
- 229930020125 aflatoxin-B1 Natural products 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002224 dissection Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229940126409 proton pump inhibitor Drugs 0.000 description 3
- 239000000612 proton pump inhibitor Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 235000011511 Diospyros Nutrition 0.000 description 2
- 244000236655 Diospyros kaki Species 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960001380 cimetidine Drugs 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- IBXPYPUJPLLOIN-UHFFFAOYSA-N dimetridazole Chemical compound CC1=NC=C(N(=O)=O)N1C IBXPYPUJPLLOIN-UHFFFAOYSA-N 0.000 description 2
- 229960000946 dimetridazole Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 201000003102 mental depression Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002235 sarcomere Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 2
- 229960000699 terbinafine hydrochloride Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 description 1
- KEQXNNJHMWSZHK-UHFFFAOYSA-L 1,3,2,4$l^{2}-dioxathiaplumbetane 2,2-dioxide Chemical compound [Pb+2].[O-]S([O-])(=O)=O KEQXNNJHMWSZHK-UHFFFAOYSA-L 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 240000004510 Agastache rugosa Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000746375 Andrographis Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010015967 Eye swelling Diseases 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- MVTQIFVKRXBCHS-SMMNFGSLSA-N N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide (10R,11R,12E,17E,19E,21S)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone Chemical compound CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c2coc(CC(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@H]1C)n2.CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@@H]2CCCN2C1=O)c1ccccc1 MVTQIFVKRXBCHS-SMMNFGSLSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241000256259 Noctuidae Species 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000274050 Platycodon grandiflorum Species 0.000 description 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000206469 Pulsatilla Species 0.000 description 1
- YDBYJHTYSHBBAU-YFKPBYRVSA-N S-methyl-L-methioninate Chemical compound C[S+](C)CC[C@H](N)C([O-])=O YDBYJHTYSHBBAU-YFKPBYRVSA-N 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108010080702 Virginiamycin Proteins 0.000 description 1
- 239000004188 Virginiamycin Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- KZFDVWZZYOPBQZ-UHFFFAOYSA-K bismuth;potassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KZFDVWZZYOPBQZ-UHFFFAOYSA-K 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 210000001669 bursa of fabricius Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960003760 florfenicol Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 229940063517 omeprazole sodium Drugs 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- KNVABRFVZVESIL-UHFFFAOYSA-N sodium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound [Na+].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C KNVABRFVZVESIL-UHFFFAOYSA-N 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229960003842 virginiamycin Drugs 0.000 description 1
- 235000019373 virginiamycin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Physiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Abstract
The invention provides an application of cinnamaldehyde in preparing feed, feed additive, veterinary drug or water-drinking preparation for preventing or treating poultry glandular gastritis and glandular stomach erosion. According to the invention, the cinnamaldehyde is added into the feed, the feed additive, the veterinary drug or the drinking preparation, so that the poultry adenomuscular gastritis and the adenomuscular stomach erosion can be effectively prevented and treated, and the use of antibiotics is avoided.
Description
Technical Field
The invention belongs to the technical field of livestock and poultry breeding, and particularly relates to an application of cinnamaldehyde in preparation of feed, feed additives, veterinary drugs or water-drinking preparations for preventing or treating poultry adenofibromyositis.
Background
Since poultry glandular myositis and muscular stomach erosion were first reported in the netherlands in 1978, the diseases occur all over the world, which brings great harm to the breeding industry and cannot be ignored. At present, cases of infectious proventriculitis frequently occur in the market, the treatment is difficult, and the loss is not small for the breeding industry. Almost all chicken flocks with proventriculitis can separate viruses, and the viruses widely occur in northeast, north China and south China.
Proventriculitis and muscular stomach erosion are common diseases of poultry, particularly broiler chicken and breeding hens, which are frequently accompanied with the diseases, the morbidity is 7-28%, the morbidity and mortality are 30-50%, the course of disease is long, the death and culling rate is high, and the incidence rate is in an ascending trend, so that great loss is caused. In a word, the adenomyositis (erosion) is a syndrome with complex causes, about 40 percent of which is caused by the mildew of a large amount of aged grains, feed raw materials and finished products; the other 40 percent of chickens and farms are infected with various viruses, including hatching embryonated chicken eggs with viruses to enable the viruses to infect the chickens and the farms one generation after another; if the virus is gonad-myositis, the disease is developed in one chicken farm, and almost 100% of the next batch is also developed; the rest 10 percent of the feed is caused by oxidation of feed raw materials, and the other 10 percent of the feed is poor in feeding management, such as poor ventilation, air moisture in a chicken house, musty and strong ammonia flavor, mycotoxin poisoning, massive proliferation of anaerobic bacteria in vivo, glandular and gastric dysfunction, increase of gastric acid secretion, glandular and gastric ulcers and muscular and gastric erosion.
The disease chicken with the adenoid gastritis is clinically mainly manifested by growth retardation, even stagnation, mental depression, disharmony of feather and fin drooping. Some patients have lacrimation and swollen eyes with respiratory symptoms, discharge white or green thin feces and have excessive stool. The scraping examination shows that the disease chicken has swollen glandular stomach like a ball, is milk white, has erosive bleeding and hyperplasia of glandular stomach wall, has ulcer focus, swollen and bleeding nipple, fuses between glandular stomach and muscular stomach nipple, has zonal bleeding and has no limit. The muscular stomach, thymus and spleen are obviously atrophied. The intestinal mucosa is fallen off, the intestinal wall is thin, and bleeding is caused to different degrees. Referring to fig. 1, fig. 1 is a photograph of a glandular myostomach of a sick chicken dissected for typical glandular myogastritis.
For the prevention and treatment of the proventriculitis, an effective treatment method has not been found for a long time, and the method is a worldwide problem, and in the prior art market, for the proventriculitis and the myogastric erosion, feed mould removal and western medicines are mainly adopted to control bacterial infection and inhibit gastric acid secretion, so that the treatment effect is poor. Patents and documents are not few, and a Chinese herbal medicine formula such as rhizoma cyperi, rhizoma atractylodis macrocephalae and cortex moutan is used for preventing and treating the adenomyositis, but the Chinese herbal medicine formula has no exact effect and is difficult to be widely used; the other type uses western medicines, such as cimetidine, aspirin, dimetridazole, amoxicillin, omeprazole sodium and the like, which not only have no stable effect and are widely used, but also use antibiotics and medicines which are used together with people, and the unsafe meat, eggs and milk are produced to cause adverse effects on the health of people. The western medicine formula patents include: penicillin, streptomycin (CN 10466429A); omeprazole (CN 107397719A); florfenicol, metronidazole, pyritinidine hydrochloride (CN 101966178A); new hope group terbinafine hydrochloride, ampicillin (CN 103394021B); gentamicin, pyritinidine (CN 101647883A); cimetidine, dimetridazole, amoxicillin, potassium citrate (CN 102983363A); amoxicillin, astragalus polysaccharides (CN 104208089A); industrial salts of penicillin, ranitidine (CN 102283886A); amoxicillin, mold remover (CN107789362A), and the like.
Patent application 201310629029.1 discloses a composition for treating chicken proventriculitis and a preparation method thereof, wherein the composition comprises the following components in parts by weight: 5-10 parts of penicillin, 5-10 parts of streptomycin, 10-3 parts of ash bark, 10-30 parts of montmorillonite and 10-30 parts of endothelium corneum gigeriae galli. Patent application 201510057201.X 'A compound preparation for treating broiler proventriculitis' comprises the following components in parts by weight: 1-5 percent of proton pump inhibitor, 5-30 percent of vitamin U, 5-30 percent of colloidal bismuth pectin and 50-91 percent of bulking agent. Wherein the proton pump inhibitor is one or more of omeprazole, rabeprazole, pantoprazole, esomeprazole, lansoprazole or salts corresponding to the proton pump inhibitor; the filler is one or more of medicinal fillers such as starch, glucose, lactose, maltose, dextrin, etc. Patent application 201510666591.0 discloses a traditional Chinese medicine oral liquid for treating chicken proventriculitis and muscular gastritis, which comprises the following raw materials in parts by weight: 20-60 parts of coptis chinensis, 50-80 parts of scutellaria baicalensis, 30-50 parts of gardenia, 10-30 parts of common andrographis herb, 10-30 parts of Chinese pulsatilla root, 8-20 parts of liquorice, 8-15 parts of wrinkled gianthyssop herb, 8-15 parts of bighead atractylodes rhizome, 8-15 parts of rhizoma atractylodis, 8-15 parts of mangnolia officinalis, 8-15 parts of poria cocos, 8-15 parts of fructus forsythiae, 8-15 parts of radix bupleuri, 8-15 parts of platycodon grandiflorum, 8-15 parts of dried orange peel and 8-15 parts of pericarpium arecae, and the raw materials are extracted by ethanol and decocted by water to prepare the traditional Chinese medicine oral liquid.
In the prior art, either antibiotic medicines are taken as main medicines or pure Chinese herbal medicines are combined to form complex components, so that the feed is not enough in the comprehensive consideration of feeding safety and efficacy. The feed additive catalogue in China requires definite components, is convenient to use, can be detected and traced, obviously cannot be realized by the prior art, is difficult to use in a feed factory, and can cause proventriculitis frequently in laying hens, the laying period is forbidden to use antibiotics and related products, even if the laying hens are used by theft, the laying hens can remain in eggs, and once the laying hens are found out, the punishment is quite serious.
Disclosure of Invention
In view of the above, the technical problem to be solved by the present invention is to provide an application of cinnamaldehyde in preparing a feed, a feed additive, a veterinary drug or a water-based preparation for preventing and treating poultry adenoid gastritis and adenoid gastric erosion, wherein the cinnamaldehyde can be added into the feed, the feed additive, the veterinary drug or the water-based preparation for effectively preventing and treating poultry adenoid gastritis and adenoid gastric erosion, thereby avoiding the use of antibiotics.
The invention provides an application of cinnamaldehyde in preparing feed, feed additive, veterinary drug or water-drinking preparation for preventing or treating poultry adenomuscular gastritis.
Preferably, when the feed additive or veterinary drug is added into the feed, the concentration of the cinnamaldehyde in the feed is 200-5000 mg/kg;
the concentration of cinnamaldehyde in drinking water prepared by the drinking water preparation is 20-2500 mg/kg.
Preferably, when the feed additive, the veterinary drug or the drinking water preparation is used for preventing poultry adenomuscular gastritis and adenomuscular stomach erosion, the concentration of cinnamaldehyde added into the feed is 250-500 mg/kg, or the concentration of cinnamaldehyde in drinking water prepared by the drinking water preparation is 20-250 mg/kg, and the using method is as follows: the preparation is used for 5-12 days.
Preferably, the using method comprises the following steps: the medicine is used for 5-12 days, and is used once after 15-45 days, and the medicine is used for 3-25 days once.
Preferably, the using method comprises the following steps: the medicine is used for 5 to 12 days, and is used once after every 20 to 25 days, and the medicine is used for 3 to 5 days.
Preferably, when the feed additive, the veterinary drug or the drinking water preparation is used for treating poultry adenomuscular gastritis and adenomuscular gastric erosion, the concentration of cinnamaldehyde in the feed is 350-1250 mg/kg when the feed is mixed with the feed, or the concentration of cinnamaldehyde in drinking water prepared by the drinking water preparation is 75-625 mg/kg, and the using method is as follows: the preparation is used for 3-15 days.
Preferably, the using method comprises the following steps: the medicine is used for 3-15 days, and is used once after every 10-30 days, and the time is 3-15 days.
Preferably, the poultry is laying poultry in the egg laying period, when the feed additive or veterinary drug is used for mixing with feed, the concentration of cinnamaldehyde in the feed is 75-250 mg/kg, or the concentration of cinnamaldehyde in drinking water prepared by a drinking water preparation is 37.5-125 mg/kg, the using time is 8-30 days/time, the cinnamaldehyde is used once every 20-45 days, and the cinnamaldehyde is used once every 8-15 days, so that the health of laying hens is ensured.
Preferably, the feed, feed additive, veterinary drug or drinking water preparation further comprises an auxiliary component for preventing or treating poultry adenomyositis and adenomyositis erosion, wherein the auxiliary component comprises plant essential oil, Chinese herbal medicine or chemical composition.
Preferably, the plant essential oil is selected from carvacrol, thymol or eugenol.
Compared with the prior art, the invention provides the application of cinnamaldehyde in preparing feed, feed additives, veterinary drugs or water-based preparations for preventing or treating poultry glandular myositis and glandular stomach erosion. According to the invention, the cinnamaldehyde is added into the feed, the feed additive, the veterinary drug or the drinking preparation, so that the poultry adenomuscular gastritis and the adenomuscular stomach erosion can be effectively prevented and treated, and the use of antibiotics is avoided.
The results show that in order to ensure effective defense and treatment of glandular gastritis (erosion), the addition concentration of the feed needs 250-500 ppm (when egg-laying poultry generates the glandular gastritis in the egg laying period, in order to not affect the egg laying and egg quality, the cinnamaldehyde concentration in the feed can be as low as more than or equal to 75mg/kg), the severe glandular gastritis is caused to virulent viruses, 1000-2000 ppm needs to be added into the feed, and the removal of diseases by hands can be basically achieved.
The above description is a scheme for preventing and treating the adenomyosis which is confirmed or obtained by experience, the concentration of the cinnamaldehyde in the feed must reach 200-5000mg/kg, but because the cause of the adenomyosis is complicated, we do not exclude that the low dose of 20-150mg/kg added in the feed or drinking water has a certain effect on preventing the adenomyosis.
Drawings
FIG. 1 is a photograph of a glandular myostomach after dissection of a diseased chicken with typical glandular myogastritis;
FIG. 2 is a photograph of dissected adenomyosis of broiler chickens of example 6 control group;
FIG. 3 is a photograph of dissected adenomyosis of broiler chickens of example 6 three experimental groups;
FIG. 4 is a photograph of the dissected adenomyosis of the chicken of example 8;
FIG. 5 is a photograph of a farm according to example 9;
FIG. 6 is a photograph of the dissected adenomyosis of the laying hen of example 9;
FIG. 7 is a photograph of a flock of chickens according to example 10 after using the product of the invention;
FIG. 8 is a photograph of a chicken farm of example 12 after using the product of the present invention;
FIG. 9 is a photograph of a chicken farm of example 13 after use of the product of the present invention;
FIG. 10 is a graph of the symptoms of the cesarean-section myogastritis of the chicken of example 14;
FIG. 11 is a graph showing the muscular gastritis symptoms at the section of the chicken flocks of example 14;
FIG. 12 is a graph showing the symptoms of the cesarean-section myogastritis of the chicken group of example 15;
FIG. 13 is a graph showing the symptoms of the cesarean-section myogastritis of the chicken group of example 15;
FIG. 14 is a graph showing the symptoms of the cesarean-section myositis of the chicken group in example 23.
Detailed Description
The invention provides an application of cinnamaldehyde in preparing feed, feed additive, veterinary drug or water-drinking preparation for preventing or treating poultry adenoid myogastritis.
In the invention, the concentration of the cinnamaldehyde in the feed is 250-5000 mg/kg, or the concentration of the cinnamaldehyde in the drinking water prepared by the drinking water preparation is 20-2500 mg/kg,
when the feed, the feed additive, the veterinary drug or the drinking water preparation is used for preventing poultry adenomyosis and adenomyosis erosion, the concentration of the cinnamaldehyde added into the feed is 250-500 mg/kg, or the concentration of the cinnamaldehyde in the drinking water prepared by the drinking water preparation is 20-250 mg/kg, and the using method comprises the following steps: the composition is used for 5-20 days.
In some preferred embodiments of the present invention, the method of use is: the medicine is used for 5 to 20 days, and is used once after 15 to 45 days, and the medicine is used for 3 to 20 days once. Can ensure that almost 100 percent of newly-entered chicken groups and duck groups which can suffer from the adenomyositis in the polluted breeding farm which originally suffers from the adenomyositis and infected poultry seedlings which are derived from the breeding farm with the adenomyositis do not suffer from the adenomyositis any more.
In other preferred embodiments of the present invention, the method of use is: the medicine is used for 5-12 days, and is used once after 15-45 days, and the medicine is used for 3-12 days once. Can ensure that almost 100 percent of newly-entered chicken groups and duck groups which can suffer from the adenomyositis in the polluted breeding farm which originally suffers from the adenomyositis and infected poultry seedlings which are derived from the breeding farm with the adenomyositis do not suffer from the adenomyositis any more.
When the feed, the feed additive, the veterinary drug or the drinking water agent is used for treating poultry adenomyositis and adenomyositis erosion, the concentration of the cinnamaldehyde in the feed is 350-1250 mg/kg when the feed is mixed and fed, or the concentration of the cinnamaldehyde in the drinking water prepared by the drinking water preparation is 75-625 mg/kg, and the using method is as follows: the preparation is used for 6-15 days. The death and culling rate is 1-2%.
In other preferred embodiments of the present invention, the method of use is: the preparation is used for 6-15 days, and is used once after every 10-25 days, and the preparation is used for 6-15 days once. The death and culling rate is 1-2%.
The traditional Chinese medicine composition is used for preventing the adenomyositis of the population with a large risk of the adenomyositis for every 15-45 days.
For young chickens and poultries which do not lay eggs, the prevention and treatment of the adenomyositis can be carried out according to the using method.
When the poultry is laying poultry in the egg producing period and is mixed with feed, the concentration of the cinnamaldehyde in the feed is 75-250 mg/kg, or the concentration of the cinnamaldehyde in a drinking water preparation is 37.5-125 mg/kg, the using time is 8-30 days/time, the cinnamaldehyde is used once every 20-45 days, and the cinnamaldehyde is used once every 8-15 days, so that the health of the laying hens is ensured.
In some embodiments of the present invention, the feed, feed additive, veterinary drug or drinking water preparation further comprises an auxiliary ingredient for preventing or treating poultry adenomyositis and adenogastral erosion, wherein the auxiliary ingredient comprises plant essential oil, Chinese herbal medicine or chemical composition. Wherein the plant essential oil is selected from carvacrol, thymol or eugenol.
According to the invention, the cinnamaldehyde is added into the feed, the feed additive, the veterinary drug or the drinking preparation, so that the poultry adenomuscular gastritis and the adenomuscular stomach erosion can be effectively prevented and treated, and the use of antibiotics is avoided.
The results show that in order to ensure effective defense and treatment of glandular gastritis (erosion), the addition concentration of the feed needs 250-500 ppm (when egg-laying poultry generates the glandular gastritis in the egg laying period, in order to not affect the egg laying and egg quality, the cinnamaldehyde concentration in the feed can be as low as more than or equal to 75mg/kg), the severe glandular gastritis is caused to virulent viruses, 1000-2000 ppm needs to be added into the feed, and the removal of diseases by hands can be basically achieved.
The above description is a scheme for preventing and treating the adenomyosis which is confirmed or obtained by experience, the concentration of the cinnamaldehyde in the feed must reach 200-5000mg/kg, but because the cause of the adenomyosis is complicated, we do not exclude that the low dosage of 25-150mg/kg added in the feed or drinking water has a certain effect on preventing the adenomyosis.
For further understanding of the present invention, the following examples are provided to illustrate the application of cinnamaldehyde provided in the present invention in preparing feed, feed additive, veterinary drug or water-based formulation for preventing or treating poultry adenofibromyositis and adenofibromyalgia erosion, and the scope of the present invention is not limited by the following examples.
Example 1
White carbon black is used for adsorbing cinnamyl aldehyde to prepare powdery or spherical feed additive containing 25 percent of cinnamyl aldehyde.
Example 2
Preparing a veterinary drug preparation containing 25% of cinnamaldehyde by using an emulsifier (Tween) at 80 ℃, water and cinnamaldehyde;
the veterinary drug preparation can be diluted into uniform liquid by being mixed with water to obtain a drinking water preparation.
Example 3
The influence of cinnamaldehyde on various production performances such as chicken weight gain, feed conversion ratio, feed intake and the like is evaluated by healthy chicken flocks, and the condition of replacing antibiotics is analyzed:
960 Chongqing Daaiyin white feather cocks were selected and randomly divided into 12 groups for blind test, each group had 8 replicates, and each replicate 10. The cinnamaldehyde products produced in example 1 were added to negative control basal diets (formula shown in table 2 below), concentrations and groups of antibiotics and cinnamaldehyde were shown in table, infrared lamps were used to maintain the temperature three days before night, natural temperature was used later, the ground was kept flat, the henhouse was modified from a pigsty, and 9.2019, 5.5.5.a.m.: and (3) weighing the chicken on an empty stomach at a ratio of 00-11: 00, feeding the chicken for 41 days, and weighing the chicken on an empty stomach at a ratio of 5: 00-11: 00 in 10 months and 16 days in the morning, wherein the results are shown in a table 1:
TABLE 1
And (4) conclusion: from table 1, the feed added with 50-500 mg/kg of cinnamaldehyde is close to or slightly superior to the antibiotic Virginiamycin which is recognized by the industry to have the best growth promoting effect.
The cinnamic aldehyde is preferably 100mg/kg, the daily gain is improved by 9.19 percent compared with the negative control, and the appropriate addition amount of the cinnamic aldehyde in the daily ration of the broiler is 50-125 mg/kg; the high dose groups 250 and 500mg/kg seem to have slightly lower feed intake than the low dose groups 50-125mg/kg, but the weight gain and feed conversion rate are slightly affected, even not affected, so that the addition range of the cinnamaldehyde in the daily ration is 75-2000 ppm, the short-term 7-15 days of prevention and treatment has no influence or little influence on the growth of poultry, but the long-term addition and use of the high dose of more than or equal to 200mg/kg are not recommended, and the high dose of cinnamaldehyde is reported to cause the growth inhibition of osteoblasts and needs to be further proved and researched. When the common poultry is used for promoting growth by replacing antibiotics, the adding concentration of the cinnamaldehyde in the feed is 25-100 mg/kg.
Example 4
Animal experiments: 144 healthy AA broiler chickens of 1 day old were selected and randomly divided into 2 treatments, 6 replicates each, and 12 chickens each.
The treatment group 1 is a blank group and is fed with basic ration;
the treatment group 2 was a test group, in which 1.5kg/T of cinnamaldehyde produced in example 1 was added to the base ration at a cinnamaldehyde addition concentration of 375 mg/kg.
The test period was 42 days. During the test, the feed and the remainder were recorded in units of each replicate group, from which the average daily gain, daily feed intake and feed-to-weight ratio were calculated.
After the test is finished, 3 test chickens close to the average weight are randomly selected from each repeating group, blood is collected from veins under wings by 10mL, serum is separated and stored at the temperature of 20 ℃ below zero for determining the content of the immunoglobulin. After blood collection, jugular vein bloodletting is slaughtered, spleen, thymus, bursa of Fabricius and other organs are picked, adipose tissues are removed, and fresh weight is quickly weighed and used for calculating immune organ indexes. The composition and nutritional ingredients of the basal diet are shown in table 2.
TABLE 2 basal diet formula and nutritional level
Raw materials | Content (wt.) | Nutritional levels | Numerical value |
Corn (corn) | 58.2 | Metabolizable energy (kcal/kg) | 3000 |
Bean pulp | 29.1 | Crude protein (%) | 21.5 |
Cottonseed protein | 4.0 | Calcium (%) | 0.92 |
Corn protein powder | 3.0 | ||
Stone powder | 1.1 | Phosphorus (%) | 0.45 |
Salt | 0.36 | Lysine (%) | 1.10 |
Calcium hydrogen phosphate | 2.1 | Egg + cysts (%) | 0.85 |
Methionine | 0.12 | ||
Lysine | 0.02 | ||
Soybean oil | 1.0 | ||
1% premix | 1 |
TABLE 3 Effect of the feed additives of the invention on broiler productivity
Treatment group 1 | Treatment group 2 | |
Average daily gain (g) | 52.43±1.43a | 55.29±1.23b |
Average daily food intake | 95.28±0.83a | 95.55±0.77b |
Material to weight ratio | 1.82±0.05a | 1.73±0.03b |
Significant difference in different letter representations of the same row
As can be seen from the data in Table 3, the average daily gain, feed intake and feed conversion ratio of treatment group 2 were improved by 5.5%, 0.3% and 4.9%, respectively.
TABLE 4 influence of the feed additive of the invention on the immune organ index of broilers
Treatment of group 1 | Treatment of 2 groups | |
Spleen index (g/kg) | 1.36±0.04a | 1.59±0.12b |
Thymus index (g/kg) | 3.30±0.13a | 3.56±0.55b |
Bursa index (g/kg) | 1.52±0.08a | 1.75±0.09b |
Significant difference in different letters in the same row
As can be seen from the data in Table 4, the spleen index, thymus index and bursal index of the treated group 2 were all increased by 16.9%, 7.9% and 15.1%, respectively.
TABLE 5 Effect of the feed additives of the present invention on serum immunoglobulins of broilers
Process 1 | Treatment 2 | |
IgG(g/l) | 2.52±0.06a | 2.79±0.08b |
IgA(g/l) | 1.13±0.15a | 1.49±0.12b |
IgM(g/l) | 1.71±0.15a | 1.88±0.09b |
Significant difference in different letters in the same row
As can be seen from the data in Table 5, the IgG, IgA and IgM concentrations in treatment group 2 were all increased by 10.7%, 31.9% and 9.9%, respectively.
By combining the indexes, the cinnamaldehyde feed additive provided by the invention can greatly improve the production performance of the broiler chicken and can remarkably enhance the immune function of the broiler chicken.
Example 5
600 white feather broilers with 30-day-old diseased and toxic proventriculitis and no death are selected and randomly divided into 3 treatments, each treatment is divided into 5 repetitions, and each repetition comprises 40 chickens.
Treatment 1 control 1 was the basal diet group,
treatment 2 control 2 is a group of commercially available antibiotics (mainly containing terbinafine hydrochloride and ampicillin) for treating proventriculitis of a new company, which is added according to a label and simultaneously fed with bismuth potassium citrate in proper amount.
The treatment 3 is a test group, 2kg/T of the cinnamaldehyde product produced in example 1 is added into the basic ration, the adding amount of the cinnamaldehyde is 500mg/kg, and the death number and the death rate of the chickens in each treatment group are counted after the chickens are fed for 15 days.
TABLE 6 therapeutic effect of the feed additive of the present invention on proventriculitis of broiler chicken
Control 1 group | Control 2 group | Treatment of 3 test groups | |
Death only counts (only) | 114±1.32a | 87±1.06b | 2.00±0.02c |
The mortality rate is% | 57.00±0.66a | 43.5±0.06b | 1.0±0.05c |
Significant difference in different letters in the same row
As can be seen from the data in Table 6, the death number and death rate of the chickens treated by adding the cinnamaldehyde feed additive are far lower than those of the chickens treated by adding the cinnamaldehyde feed additive in two control groups, so that the feed additive has a good curative effect on proventriculitis and myogastritis, the curative effect of the feed additive is remarkably superior to that of conventionally used antibiotic drugs, and the feed additive is safer and more stable than the antibiotic drugs.
In conclusion, feeding experiments prove that the feed additive can obviously improve the production performance of the broiler chicken and obviously improve the immune function of the broiler chicken, thereby reducing the occurrence of the chicken with the gastritis and the proventriculitis, having good curative effect on the chicken with the gastritis and the proventriculitis, reducing the death rate and reducing the number of dead chickens.
Example 6
In the experiment for treating the gallinaceous proventriculitis, 4 experimental groups are set, the experiment 1-4 groups adopt the cinnamaldehyde product produced in the example 1, 500, 1000, 1500 and 2000mg/kg are sequentially added into basic daily ration, and a 5 th group of control groups adopt the basic daily ration. Feeding for 12 days.
The modeling experiment method of the sick chicken comprises the following steps:
preparing a mildew feed: under the conditions of 28 ℃ and 85% humidity, the water content of the feed is 25%, the feed is turned and mixed for 2 times per day for 4 consecutive days, and the feed containing the aflatoxin B1 is obtained for standby after drying, and the content of the obtained pathogenic aflatoxin B1 is 65.29 ug/kg;
secondly, the broiler chickens continuously eat the moldy feed for 10 days, and when the broiler chickens have proventriculitis, the modeling is successful.
Through comparison, the tests 1-4 groups mainly carry out comparison and determination through three indexes, namely, production performance indexes (average daily feed intake, average daily gain and feed conversion ratio), immune indexes (immunoglobulin content) and morphological indexes (the shapes of chicken stomachs and glandular stomachs).
The results are shown in figures 2 to 3, figure 2 is a photograph of the dissected glandular stomach of the broiler chicken of the control group in example 6, and the dissected figure 2 shows that the broiler chicken of the control group 5 has glandular stomach swelling and sarcogastric erosion which are typical symptoms of chicken proventriculitis. FIG. 3 is a photograph of dissected adenomyosis of broilers of three experimental groups of example 6, and the dissected adenomyosis of the three experimental groups of 500, 1000 and 1500mg/kg shown in FIG. 3 are normal and have no lesion. In FIG. 3, the glandular muscular stomach was dissected from three test groups of 500, 1000, and 1500mg/kg in order from left to right.
The results of the production performance index and the immunity index after the multiple comparisons are shown in tables 7 and 8:
TABLE 7 comparison of the Performance of broiler chickens in each group
TABLE 8 broiler immunoglobulin comparison (μ g/mL) of groups
Test 1 group | Test 2 groups | Test 3 groups | Test 4 groups | Control group 5 | |
IgG | 2923.65±0.29 | 3026.13±0.23 | 3567.29±0.12 | 3489.26±0.22 | 2735.80±0.98 |
IgM | 823.24±0.66 | 929.35±0.73 | 1079.57±0.44 | 998.63±0.37 | 795.47±0.63 |
IgA | 361.64±0.33 | 408.34±0.32 | 436.53±0.42 | 457.33±0.55 | 319.37±0.12 |
The experiment result shows that 500-2000mg/kg of the feed can be added to effectively treat proventriculitis of chickens caused by aflatoxin B1, and intestinal health of broilers can be effectively improved. The growth performance of 500mg/kg broiler chicken is optimal, the feed intake and the weight gain are reduced to some extent along with the increase of the cinnamaldehyde concentration, but the feed conversion rate is improved more and more, and the contents of IgG, IgM and IgA can be improved by 500mg/kg, 1000 mg/kg, 1500mg/kg and 2000mg/kg of cinnamaldehyde. The daily gain and the feed conversion rate of the control group are far lower than those of each test group, the feed intake is small, the overfeeding phenomenon is serious, and the feed loss is as high as 21.81%.
The test conclusion shows that 500-2000mg/kg of feed can effectively treat the proventriculitis of the chicken caused by the mould, and all production performances are far better than those of a control group, even though the initial weight of 479.36 g of the control group 2 is far heavier than 426.54-429.73 g of the test group 1-4, and the health condition is good.
Example 7
More than 20 million white feather broilers in a chicken farm in 4 months in 2019 of Xinjiang Taiquan group Limited company have proventriculitis, and the reaction is serious, 600mg/kg (containing 150mg/kg of cinnamaldehyde) of the cinnamaldehyde feed additive produced in the embodiment 1 is added into each ton of feed, so that the reaction is basically ineffective, and the fact that the feed with the cinnamaldehyde concentration lower than 150mg/kg is basically ineffective in preventing and treating the serious white feather broilers with the proventriculitis is shown.
Example 8
The Weifang city of Shandong province has been imitatied, 26384m, a prefecture-integrated agriculture development Limited company, Law: some Liu, 134 is a domestic contract chicken company, which provides breeders with chicks, feeds and poultry drugs and recovers chickens, 30 thousand chickens are 817 chickens per month, 120 thousand chickens are eaten as big meat, all bred chickens have adenomyositis from 2019, 10 months to the present, and after dissection, see figure 4, and as can be seen from figure 4, the glandular stomach is congested and swollen, and the sarcogenic stomach becomes black and erosive:
all the chickens fed 2000 g of the feed additive containing 25% of cinnamaldehyde produced in example 1 per ton of the feed are recovered to feed after 10 days of continuous use, and the adenoid gastritis symptom disappears completely. Farmers would like this product very much.
The client contract chicken is changed from 11 months in 2019, the feed additive containing 25% of cinnamaldehyde and produced in example 1 is added into the feed, each ton of the feed is mixed with 1500 g of the feed for 10 days, and the glandular myositis does not occur in the later growth process of all chicken groups. The product becomes a necessary product for the same agriculture development company of \26384m.
Example 9
37075of city of lotus, Shandong province, Huang Anzhen of city, 186 x, hen breeding, 2 ten thousand hen breeding, see FIG. 5, and FIG. 5 is a photograph of the farm in example 9. The farmer and the chickens which have been laying at the peak of egg production in 5 months of 2020 have adenomyositis, the feed intake is reduced, the egg production is reduced by 10%, the chickens which have little feed intake and are in mental depression are dissected, the adenomyositis stomachs are as shown in figure 6, and the adenomyositis stomachs are obviously swollen.
The feed contains 25% of cinnamaldehyde produced in example 1, 500 g (125 mg/kg) of cinnamaldehyde is added to each ton of feed, the feed is continuously used for 10 days, the feed intake is recovered to a normal level, the egg laying is recovered to a normal level, and the chicken flock is recovered to a normal production.
Example 10
Shandong chatting about persimmon garden Zhennanguo, one of the grand, 156, each of the farmers, 8 thousands of meat in each batch, severe proventriculitis developed in 2019 in 2-9 months, from 11 months to the present in 2019, 25% cinnamaldehyde in the feed opening prepared in example 1, 1500 g cinnamaldehyde in each ton of feed, 10 days of continuous use, a total of 5 batches of 40 ten thousand 817 thousand chickens used, and the chickens of the farmers have no proventriculitis, and the chicken flocks are all healthy as shown in FIG. 7.
Example 11
The method comprises the steps of culturing laying hens in Shandong province Yizishi 37075and Cheng county Huang Anzhen, culturing a certain Guo, 138 Yu xi, culturing the laying hens, breeding 1 ten thousand young chickens, enabling the young chickens to have adenoid gastritis and decrease the feed intake, adding the cinnamaldehyde product containing 25% of the cinnamaldehyde product produced in example 1 into the feed in the year 2020 and 5 months, continuously using the feed for 10 days, recovering the feed intake to a normal level, and recovering the normal growth of young chicken flocks.
Example 12
Anhui Hefei Mao Yuan company (business person: Luo Jing 182X)
2 ten thousand 817 chickens are used by a farmer in Biqian town of Lanxi county, Xuancheng City, 8 months in 2020, 2kg of the product produced in example 1 is added into each ton of feed after opening the feed, the feed is continuously used for 10 days, and the glandular myositis does not occur in the whole chicken group within 30 days. Referring to fig. 8, fig. 8 is a photograph of the chicken farm of example 12 after using the product of the present invention.
Example 13
Some 135 x y of the city of commercially available commercial beans in Henan
In the persimmon garden of Liuzhaicun bean collected in Yongcheng county of Shang city, Henan province, the company has 2 ten thousand 817 chickens, 2kg of the cinnamaldehyde product containing 25% produced in example 1 is added to each ton of feed from the starter feed, the feed is continuously used for 10 days, and the whole chicken flock grows at the later stage without adenoid gastritis. Referring to fig. 9, fig. 9 is a photograph of the chicken farm of example 13 after using the product of the present invention.
Example 14
In the individual breeding of Yuanmen country peach source village in Yuanyang county, Xinxiang city, Henan province, 183X Y from Kudzuvine had feed intake of 5000 chickens (10 days old) only 50% of normal level, and the autopsy for the symptoms of the muscular gastritis is shown in figure 10, as shown in figure 10, the swelling of glandular stomach is large, and as shown in figure 11, the erosion of muscular stomach, the stratum corneum is almost perforated, and the diagnosis is confirmed.
2 kg/ton of the cinnamaldehyde product containing 25% produced in example 1 was mixed with the feed, feeding was recovered by more than 70% on the third day, 99% of the chickens returned to the normal feeding state on the fifth day after use, 12 chickens died in total, the anatomically recovered chickens had disappeared the proventriculitis symptom. However, 1% of the chickens had almost stopped feeding, had the symptoms of proventriculitis when dissected and were rejected. The previous drugs for treating proventriculitis with antibiotics have no effect.
Example 15
8000 chickens (22 days old) of 817 from Yuanmen county Yuanyang city, Xinxiang province (138 x) feed intake is 50% of normal amount before use, proventriculitis is serious, the state of the whole chicken group is not good, and the dissected dead chicken have cracked and damaged glandular stomach cuticle, and the glandular stomach hyperemia and swelling and the sarcomere of the sarcomere completely fall off in a figure 12.
The feed is mixed with 1 kg/ton of the product containing 25% of cinnamyl aldehyde produced in example 1, feeding is recovered to 80% after 3 days after use, 98% of chickens recover to a normal feeding state after 5 days after use, 16 chickens die in total, the glandular gastritis symptoms of the anatomically recovered chickens disappear, and only very few mild myogastritis symptoms exist. But less than 2 percent of the chickens fed by the feed are almost stopped, the symptoms of the anatomical proventriculitis are obvious, the chickens dissected and recovered on the 8 th day can not find the symptoms of the muscular gastritis any more, and the chickens hardly fed by the feed have the symptoms of the proventriculitis and the muscular gastritis.
Example 16
In 6 late 6 months in 2018 in Hunan Xiangjia animal husbandry, nearly 3 million chickens in a chicken farm of a generation of farmers are abnormally fed, the spirit is not good and proventriculitis is suspected, and the autopsy proves that 800 g/t (200 mg/kg of cinnamaldehyde) of the cinnamaldehyde feed additive produced in example 1 is fed into the feed from 28 days 6 months, and the reaction and the feed intake of the farmers are improved and the growth is normal after 10 days 7 months.
In the first 7 th month, the company has a breeding farm with twenty thousand chickens and thirty thousand chickens, proventriculitis is confirmed by a caesarean section, 1000 g/ton (250 mg/kg) of the cinnamaldehyde feed additive produced in example 1 is mixed in the feed, and the mixture is mixed for 12 days and is completely recovered to be normal.
Example 17
In a 20-million chicken farm with proventriculitis occurring in 12 months and 1 day in 2019 and belonging to an economic adult feed factory of five-channel Anhui in the economic development district of Union Town in the fixed town county of Union Town City, 300kg of the cinnamaldehyde feed additive produced in example 1 is provided for free, the cinnamaldehyde feed additive is received in 3 days in 12 months and 3 days in 2019 at a ratio of 20:31 seconds (from the well of the consignee), 1.0 kg/ton of the cinnamaldehyde feed additive is added into the feed at night, and all chickens are normal after 15 days of administration.
Example 18
In 2019, 20 days in 4 months, proventriculitis and enteritis commonly occur to broiler users (hope six and Sunday) of Shandong Weifang Xinrong feed Limited company (hope six and Sunday) due to seasonal reasons, the antibiotic prevention amount is invalid, 4 tons of cinnamaldehyde feed additive (100 mg/kg of cinnamaldehyde) produced in example 1 freely given by the Shandong Weifang Xinrong feed is added into the feed at the late 5 months and 7 days later, the market feedback has obvious effect after half a month, and particularly, the feed is used from 1 day old chicks, so that the feed is well managed, has no proventriculitis and obviously reduces the incidence of poor management. By the month of febrile and humid season proventriculitis began to worsen again, with some relief from addition to 600 g/t (cinnamaldehyde 150mg/kg), but poor management and barton conditions, especially in poorly ventilated chicken farms, were not used (1 kg/t was recommended) even with addition to 600 g/t (cinnamaldehyde 150mg/kg) (contact Qu teacher 135).
Example 19
159 x y x y x y x.
Symptoms are: proventriculitis occurs, 1.5kg of Jingluan-50B is continuously added into each ton of feed for 9 days, and all the feeds are recovered to be normal.
Example 20
One 156X Y H A V C B C A V C A V C A C B C A C B C A C B C A C B C A C B C A C B C A C B C A C B C A C B C A C B C.
Example 21
Shang guan Zhen of Shang Han county, Henan province, and Zi (Mobile phone 135X)
When 817 kinds of chickens are bred, proventriculitis begins to occur at 15 days, the symptom of anatomical proventriculitis can be clearly diagnosed, 1.5 kg/ton of the cinnamaldehyde feed additive produced in the example 1 is added into the feed, the feed is continuously used for 8 days, the whole chicken crowd normally feeds, and the symptom of anatomical proventriculitis is obviously slight.
Example 22
A species of a certain (cell phone 186 x) bred in guan tai town of Handan city, Hebei province: 817, the chickens grow unevenly, the ingestion is only about 60% of the normal level, the dissected glandular gastric ulcer is serious, 1.5 kg/ton of the cinnamaldehyde feed additive produced in the example 1 is added into the feed immediately, the feed is continuously used for 12 days, the whole chicken group ingests the chickens which are normal, and the dissected chickens are difficult to see the glandular gastritis symptoms again.
Example 23
The method comprises the following steps of (1) chatting in Shandong province city Gaotang county, Qing Ping Tou Liuhai village, breeding a certain Liu (cell phone 182. x.) with chicken breed: 817, uneven growth, listlessness, poor appetite, large swelling of the dissected glandular stomach, severe erosion of the muscular stomach, as shown in FIG. 14, for accurate diagnosis.
2 kg/ton of the cinnamaldehyde feed additive produced in the example 1 is added into the feed, the feed is continuously used for 12 days, the whole chicken flock is relatively good in alignment, the feeding is recovered to be normal, and only the chickens with the adenoid myogastritis symptoms cannot be seen through dissection.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (10)
1. Application of cinnamaldehyde in preparing feed, feed additive, veterinary drug or water-drinking preparation for preventing or treating poultry adenoid myogastritis.
2. The use according to claim 1, wherein when the feed additive or veterinary drug is added to a feed, the concentration of cinnamaldehyde in the feed is 200-5000 mg/kg;
the concentration of cinnamaldehyde in drinking water prepared by the drinking water preparation is 20-2500 mg/kg.
3. The use of claim 1, wherein when the feed additive, veterinary drug or drinking water preparation is used for preventing poultry adenoid gastritis and adenoid gastric erosion, the concentration of cinnamaldehyde added to the feed is 250-500 mg/kg, or the concentration of cinnamaldehyde in drinking water prepared from the drinking water preparation is 20-500 mg/kg, and the use method is as follows: the preparation is used for 5-12 days.
4. The use according to claim 3, characterized in that the method of use is: the medicine is used for 5-12 days, and is used once after 15-45 days, and the medicine is used for 3-25 days once.
5. The use according to claim 3, wherein the method of use is: the medicine is used for 5 to 12 days, and is used once after every 20 to 25 days, and the medicine is used for 3 to 5 days.
6. The use of claim 1, wherein when the feed additive, veterinary drug or drinking water preparation is used for treating poultry adenoid gastritis and adenoid gastric erosion, the concentration of cinnamaldehyde in the feed is 350-1250 mg/kg when the feed is mixed with the feed, or the concentration of cinnamaldehyde in drinking water prepared by the drinking water preparation is 75-625 mg/kg, and the use method is as follows: the preparation is used for 3-15 days.
7. The use according to claim 6, wherein the method of use is: the preparation is used for 3-15 days, and is used once after every 10-30 days, and the preparation is used for 3-15 days once.
8. The application of claim 1, wherein the poultry is laying poultry in an egg laying period, and when the feed additive or veterinary drug is mixed with a feed, the concentration of the cinnamaldehyde in the feed is 75-250 mg/kg, or the concentration of the cinnamaldehyde in drinking water prepared by a drinking water preparation is 37.5-125 mg/kg, the using time is 8-30 days/time, and the cinnamaldehyde is used once every 20-45 days and 8-15 days once to ensure the health of laying hens.
9. The use according to claim 1, wherein the feed, feed additive, veterinary drug or drinking water preparation further comprises an auxiliary component for preventing or treating poultry adenomyositis and adenomygastric erosion, and the auxiliary component comprises plant essential oil, Chinese herbal medicine or chemical composition.
10. Use according to claim 9, wherein the plant essential oil is selected from carvacrol, thymol or eugenol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011591319.8A CN114680233A (en) | 2020-12-29 | 2020-12-29 | Application of cinnamaldehyde in preparing feed, feed additive, veterinary drug or water-drinking preparation for preventing or treating poultry adenoid myogastritis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011591319.8A CN114680233A (en) | 2020-12-29 | 2020-12-29 | Application of cinnamaldehyde in preparing feed, feed additive, veterinary drug or water-drinking preparation for preventing or treating poultry adenoid myogastritis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114680233A true CN114680233A (en) | 2022-07-01 |
Family
ID=82132804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011591319.8A Pending CN114680233A (en) | 2020-12-29 | 2020-12-29 | Application of cinnamaldehyde in preparing feed, feed additive, veterinary drug or water-drinking preparation for preventing or treating poultry adenoid myogastritis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114680233A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108157663A (en) * | 2018-01-17 | 2018-06-15 | 上海美农生物科技股份有限公司 | Poultry feed additive and corresponding feed for salmonella |
CN109329609A (en) * | 2018-11-28 | 2019-02-15 | 辽宁威兰生物技术有限责任公司 | One kind containing mint flavored composite essential oil and feed addictive and application |
CN109601721A (en) * | 2019-01-31 | 2019-04-12 | 何诚 | One breeding plants field deodorization and reduces the compound preparation of mycotoxin in animal and fowl fodder |
-
2020
- 2020-12-29 CN CN202011591319.8A patent/CN114680233A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108157663A (en) * | 2018-01-17 | 2018-06-15 | 上海美农生物科技股份有限公司 | Poultry feed additive and corresponding feed for salmonella |
CN109329609A (en) * | 2018-11-28 | 2019-02-15 | 辽宁威兰生物技术有限责任公司 | One kind containing mint flavored composite essential oil and feed addictive and application |
CN109601721A (en) * | 2019-01-31 | 2019-04-12 | 何诚 | One breeding plants field deodorization and reduces the compound preparation of mycotoxin in animal and fowl fodder |
Non-Patent Citations (6)
Title |
---|
柴建亭, 等: "肉桂醛对肉鸡生长性能、养分利用率及肉质的影响", 《中国饲料》, no. 18, pages 33 - 37 * |
柴建亭;胡梅;张书汁;: "肉桂醛对肉鸡生长性能、养分利用率及肉质的影响", 中国饲料, no. 18, 20 September 2018 (2018-09-20), pages 33 - 37 * |
王克敏,等: "《蛋鸡简约化养殖技术》", 30 June 2016, 河北科学技术出版社, pages: 147 * |
胡梁斌,等: "《黄曲霉毒素危害及其控制》", 31 July 2018, 中国轻工业出版社, pages: 133 * |
陈启荣: "《食品添加剂化学》", 31 May 1990, 杭州:杭州市食品工业协会;杭州:杭州市食品研究所, pages: 137 * |
陈鹏举: "《禽病诊治原色图谱》", 30 June 2017, 河南科学技术出版社, pages: 71 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110100956A (en) | It is a kind of with anti-oxidant and immunoloregulation function " acid+essential oil " coating type feed addictive and its preparation method and application | |
CN110090279B (en) | Traditional Chinese medicine composition for preventing and treating avian gout and preparation and use methods thereof | |
CN105663546B (en) | Traditional Chinese medicine composition for treating proventriculitis of chicken | |
CN111905019A (en) | Traditional Chinese medicine formula for regulating intestinal tracts of cultured animals and preparation method thereof | |
CN101209330A (en) | Compound Chinese medicinal granule with heat-clearing and detoxication, worm-expelling and liver-protecting efficacy | |
CN112807348B (en) | Disease-resistant and growth-promoting traditional Chinese medicine compound, and preparation and application thereof | |
CN106306548B (en) | Feed additive for preventing and treating proventriculitis and myogastritis of chicken | |
CN101209296A (en) | Chinese medicinal granule with worm-expelling liver-caring, hemostasis and dysentery-stopping efficacy | |
CN109999117A (en) | Prevent and treat enteritis, bacillary dysentery, dysentery, intractable diarrhea Chinese medicine composition | |
CN106511675A (en) | Medicine for preventing and treating poultry diseases and preparation method of medicine | |
CN105535406A (en) | Traditional Chinese medicine composition for preventing and treating livestock respiratory disease | |
CN114680233A (en) | Application of cinnamaldehyde in preparing feed, feed additive, veterinary drug or water-drinking preparation for preventing or treating poultry adenoid myogastritis | |
CN114886961A (en) | Traditional Chinese medicine composition for treating/preventing avian gout and preparation method and application thereof | |
CN110812389B (en) | Soluble granule for improving pig immunity and preparation method thereof | |
CN113559137A (en) | Granulating method of veterinary drug granules | |
CN110755604A (en) | Pharmaceutical composition for preventing and treating poultry adenofibromyositis and application thereof | |
CN107789394B (en) | Composition for treating livestock and poultry diarrhea | |
CN105192430A (en) | Chicken feed additive for preventing chicken diseases | |
CN112451589A (en) | Pharmaceutical composition for treating pullorum disease and preparation method thereof | |
CN111760004A (en) | Traditional Chinese medicine granules for preventing and treating livestock and poultry influenza and application thereof | |
CN105770054A (en) | Pharmaceutical composition for preventing and treating chicken coccocidiosis, additive and feed | |
CN104688883B (en) | A kind of Chinese medicine composition of kuh-seng containing wolf's milk and radix scutellariae and preparation method thereof | |
CN110150486A (en) | A kind of feed addictive for preventing and treating the intestines problems such as milking sow constipation diarrhea | |
CN115607614B (en) | Traditional Chinese medicine composition for treating colibacillosis of livestock and poultry and preparation method thereof | |
CN114073728B (en) | Traditional Chinese medicine composition for preventing and treating salpingitis of laying hens and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |